We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





FlashDx Launches New Respiratory and MRSA/SA Panels at MEDICA 2025

By LabMedica International staff writers
Posted on 17 Nov 2025

FlashDx is introducing two new molecular diagnostic assays at MEDICA 2025—the Respiratory Panel 2 and the MRSA/SA Panel. More...

The launch of these assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing the company’s commitment to advancing near-patient molecular diagnostics through innovation and automation. FlashDx will also demonstrate its fully automated multiplex molecular diagnostic system, powered by its proprietary sSPRT (semi-Solid Phase Real-Time PCR) technology.

The company is debuting Respiratory Panel 2, which targets additional respiratory pathogens to complement the existing Respiratory Panel 1.1. By broadening organism coverage, the new panel is intended to increase diagnostic flexibility while maintaining a syndromic testing approach. FlashDx is also launching an MRSA/SA Panel for rapid and precise detection of Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing routine screening and infection control needs in hospitals and clinics.

FlashDx is demonstrating its sSPRT powered platform at MEDICA 2025. The sSPRT platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics. Built to comply with the EU’s stringent IVD Regulation standards, the system maintains full regulatory integrity without sacrificing speed or flexibility. Its expandable, multi-slot instrumentation provides true random access to a wide range of disease panels and sample types—anytime and anywhere—allowing laboratories to scale testing confidently while meeting global quality and safety requirements

Attendees can meet FlashDx in Hall 3, Booth H26 at MEDICA 2025 to review the new assays and discuss opportunities for collaboration. Founded by U.S. and European industry experts with Silicon Valley know-how, FlashDx offers a turnkey, sample-to-answer platform and a portfolio of syndromic infectious disease cartridges, with plans to expand into oncology and other disease areas.

Related Links:
FlashDx

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.